JPS5854122B2 - 新規なエルゴットアルカロイド薬剤およびその製法 - Google Patents

新規なエルゴットアルカロイド薬剤およびその製法

Info

Publication number
JPS5854122B2
JPS5854122B2 JP51123463A JP12346376A JPS5854122B2 JP S5854122 B2 JPS5854122 B2 JP S5854122B2 JP 51123463 A JP51123463 A JP 51123463A JP 12346376 A JP12346376 A JP 12346376A JP S5854122 B2 JPS5854122 B2 JP S5854122B2
Authority
JP
Japan
Prior art keywords
polymer
drug according
item
drug
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51123463A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5251014A (en
Inventor
カールハインツ・オツトー
フオルカー・ハルトマン
ルードヴイヒ・パツト
ロター・エールハルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPS5251014A publication Critical patent/JPS5251014A/ja
Publication of JPS5854122B2 publication Critical patent/JPS5854122B2/ja
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP51123463A 1975-10-17 1976-10-16 新規なエルゴットアルカロイド薬剤およびその製法 Expired JPS5854122B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2546577A DE2546577B2 (de) 1975-10-17 1975-10-17 Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden

Publications (2)

Publication Number Publication Date
JPS5251014A JPS5251014A (en) 1977-04-23
JPS5854122B2 true JPS5854122B2 (ja) 1983-12-02

Family

ID=5959411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51123463A Expired JPS5854122B2 (ja) 1975-10-17 1976-10-16 新規なエルゴットアルカロイド薬剤およびその製法

Country Status (28)

Country Link
JP (1) JPS5854122B2 (enExample)
AT (1) AT362510B (enExample)
AU (1) AU508628B2 (enExample)
BE (1) BE847368A (enExample)
CA (1) CA1079641A (enExample)
CH (1) CH643737A5 (enExample)
CS (1) CS199647B2 (enExample)
DE (1) DE2546577B2 (enExample)
DK (1) DK146194C (enExample)
ES (1) ES452420A1 (enExample)
FI (1) FI762875A7 (enExample)
FR (1) FR2327764A1 (enExample)
GB (1) GB1560406A (enExample)
GR (1) GR61268B (enExample)
HK (1) HK3183A (enExample)
HU (1) HU172533B (enExample)
IE (1) IE43778B1 (enExample)
IL (1) IL50686A (enExample)
MY (1) MY8400063A (enExample)
NL (1) NL184558C (enExample)
NO (1) NO144468C (enExample)
NZ (1) NZ182341A (enExample)
PH (1) PH14513A (enExample)
PT (1) PT65719B (enExample)
SE (1) SE430379B (enExample)
SG (1) SG63082G (enExample)
SU (1) SU1165223A3 (enExample)
ZA (1) ZA766166B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102882996B1 (ko) * 2025-04-07 2025-11-07 (주)휴마스 액체크로마토그래피와 막전도도 측정모듈 및 개량된 uv산화반응기를 이용하는 분획된 수중 탄소 및 질소 측정장치 및 이를 이용한 측정방법

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
WO1980001242A1 (fr) * 1978-12-21 1980-06-26 Sandoz Ag Preparations galeniques
US4411882A (en) 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
ES2039287T3 (es) * 1987-01-14 1993-09-16 Ciba-Geigy Ag Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles.
FR2610827B1 (fr) * 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
DE4401646A1 (de) * 1994-01-21 1995-07-27 Krewel Werke Gmbh Optimal freisetzende Kava-Extrakte
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
AU761994C (en) * 1997-12-22 2004-01-08 Merck Sharp & Dohme Corp. Molecular dispersion composition with enhanced bioavailability
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7771746B2 (en) 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
EP1512403A1 (en) * 1999-12-03 2005-03-09 Polichem S.A. Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
DE60309356T2 (de) * 2003-06-27 2007-08-30 Bioprogress S.P.A. Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175430A (en) * 1966-04-07 1969-12-23 Sandoz Ltd Pharmaceutical Compositions containing Ergot Alkaloids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL PHARM ACEUTICAL SCIENCE=1966 *
THE MERCK TRDEX *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102882996B1 (ko) * 2025-04-07 2025-11-07 (주)휴마스 액체크로마토그래피와 막전도도 측정모듈 및 개량된 uv산화반응기를 이용하는 분획된 수중 탄소 및 질소 측정장치 및 이를 이용한 측정방법

Also Published As

Publication number Publication date
DK146194B (da) 1983-07-25
AU508628B2 (en) 1980-03-27
SG63082G (en) 1983-09-09
IL50686A (en) 1979-05-31
AT362510B (de) 1981-05-25
PH14513A (en) 1981-08-24
PT65719A (fr) 1976-11-01
GB1560406A (en) 1980-02-06
FI762875A7 (enExample) 1977-04-18
ES452420A1 (es) 1978-04-16
HU172533B (hu) 1978-09-28
DE2546577A1 (de) 1977-04-21
NL7611295A (nl) 1977-04-19
DK146194C (da) 1984-01-02
CS199647B2 (en) 1980-07-31
NO763446L (enExample) 1977-04-19
ATA767976A (de) 1980-10-15
NO144468C (no) 1981-09-09
ZA766166B (en) 1978-05-30
GR61268B (en) 1978-10-17
DK454176A (da) 1977-04-18
DE2546577B2 (de) 1981-04-02
SE7611189L (sv) 1977-04-18
CA1079641A (en) 1980-06-17
IE43778B1 (en) 1981-05-20
NL184558C (nl) 1989-09-01
NO144468B (no) 1981-06-01
BE847368A (fr) 1977-04-15
IE43778L (en) 1977-04-17
PT65719B (fr) 1978-06-12
IL50686A0 (en) 1976-12-31
FR2327764A1 (fr) 1977-05-13
NL184558B (nl) 1989-04-03
HK3183A (en) 1983-01-20
SE430379B (sv) 1983-11-14
JPS5251014A (en) 1977-04-23
FR2327764B1 (enExample) 1979-03-02
AU1875476A (en) 1978-04-20
SU1165223A3 (ru) 1985-06-30
MY8400063A (en) 1984-12-31
CH643737A5 (en) 1984-06-29
NZ182341A (en) 1978-09-20

Similar Documents

Publication Publication Date Title
JPS5854122B2 (ja) 新規なエルゴットアルカロイド薬剤およびその製法
AU2002222567B2 (en) Composition improved in solubility or oral absorbability
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
PL185604B1 (pl) Preparat farmaceutyczny zawierający bromowodorek darifenacyny
OA11518A (en) Novel process for manufacturing paroxitine solid dispersions.
HUP0004050A2 (hu) Javított oldódású itrakonazol, eljárás ennek előállítására és ezt tartalmazó orális gyógyszerkészítmény
JPS5925316A (ja) 作用時間の長いスロ−・リリ−ズ薬剤組成物及びその製法
JPH01308231A (ja) 安定化された医薬組成物および製造法
CA1146545A (en) Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
KR101538985B1 (ko) 타다라필 구강붕해필름 및 이의 제조방법
JPH0769874A (ja) カプセル形態のユビデカレノン経口製剤
FI84230B (fi) Foerfarande foer laddning av vattensvaellbara, vattenoloesliga polymerer med medroxiprogesteronacetat.
JP5225084B2 (ja) ７−［（ｅ）−ｔ−ブチルオキシミノメチル］カンプトテシンの改良された経口吸収のための即効型治療システム
WO2003086405A1 (en) Solid dispersion composition
JP2009506027A (ja) 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
JPH0361644B2 (enExample)
KR0172134B1 (ko) 고형 제제
KR102294171B1 (ko) 난용성 약물의 가용화제를 이용한 고체분산체 제조
JP2025511145A (ja) Ｘ８４２製剤
CN108815128B (zh) 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法
KR102760108B1 (ko) 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제
JP2008518909A (ja) 非水性極性溶媒中の１０−ヒドロキシカンプトテシン化合物の溶解度を増加させるための薬剤製剤
JPH0141125B2 (enExample)
KR100561318B1 (ko) 아테놀올을 함유하는 투명 연질 캡슐
KR100201907B1 (ko) 비페닐디메틸디카르복실레이트를 가용화시킨 연질캅셀제